Shared Learning Agenda Questions That Were Addressed by Projecta
| Shared Learning Agenda: 2015–2020 | EECO | SIFPO2 (MSI) | SIFPO2 (PSI) | MCSP | LEAP |
|---|---|---|---|---|---|
| Madagascar, Zambia | Nigeria | Nigeria, Zimbabwe | Kenya, Zambia | Kenya, Nigeria, Zambia | |
| A. Client demand | |||||
| 1. What are the profile(s) of the clients who will use this product? | Xb | X | X | X | |
| a. Is there or would there be demand for this product among subpopulations with high unmet need for FP (e.g., women in lower wealth quintiles, PP women, adolescents, WLHIV, PAC clients)? | (x)c | (x) | (x) | (x) | |
| b. Will introduction of the hormonal IUD help reach new FP users (i.e., current non-users)? | X | X | (x) | X | |
| c. To what degree will introduction of the hormonal IUD result in “switching” and from what methods? | X | X | (x) | X | |
| 2. Does the hormonal IUD have the potential to “revitalize” the IUD market in FP2020 countries? | |||||
| a. Would demand for the hormonal IUD be higher than demand for the copper IUD has been? | (x) | (x) | (x) | ||
| 3. Would introduction of the hormonal IUD increase FP use overall/increase contraceptive prevalence rate(s)? | |||||
| a. Can scale-up of this product help meet FP2020 goals? | |||||
| 4. How do continuation rates of the hormonal IUD compare to continuation rates of other LARCs? | (x) | (x) | (x) | X | |
| 5. Does immediate postpartum access to the hormonal IUD increase use of postpartum FP overall? | |||||
| B. Marketing | |||||
| 6. What are effective demand creation strategies with different populations and in different sectors? | (x) | (x) | (x) | ||
| 7. Can promotion of FP including the hormonal IUD be integrated into other health sectors? | (x) | ||||
| C. Service delivery | |||||
| 8. How can we overcome barriers that have impacted provision of copper IUD when introducing hormonal IUD? | (x) | (x) | (x) | (x) | (x) |
| 9. What are health care providers' perceptions of this product? | X | X | X | X | X |
| 10. What are effective service delivery models for hormonal IUD provision? How does it differ by context? | (x) | (x) | (x) | (x) | (x) |
| a. What are effective provider training strategies for the hormonal IUD? | (x) | ||||
| D. Noncontraceptive attributes | |||||
| 11. How does knowledge of noncontraceptive attributes of the hormonal IUD affect uptake and use? | X | (x) | (x) | X | |
| a. What noncontraceptive attributes are most attractive to women in different contexts? | X | (x) | (x) | X | |
| b. What noncontraceptive attributes are seen as most beneficial by providers? | X | (x) | (x) | (x) | X |
| 12. What are perceptions of amenorrhea among providers and various client segments? | (x) | (x) | (x) | (x) | X |
| 13. Can scale-up of the hormonal IUD help reduce rates of anemia? | |||||
| E. Cost-effectiveness and pricing | |||||
| 14. To what extent is the hormonal IUD cost-effective compared to other FP methods including other LARCs? | X | ||||
| 15. What is the willingness-to-pay for the hormonal IUD among different populations of clients/groups? | (x) | ||||
Abbreviations: EECO, Expanding Effective Contraceptive Options; FP, family planning; IUD, intrauterine device; LARCs, long-acting reversible contraceptives; LEAP, Learning about Expanded Access and Potential; MCSP, Maternal and Child Survival Program; MSI, Marie Stopes International; PAC, postabortion care; PP, postpartum; PSI, Population Services International; SIFPO-2, Support for International Family Planning and Health Organizations; WLHIV, women living with HIV.
↵a This table is intended to summarize evidence collected across countries and projects, but not all results are reflected in this synthesis paper. For additional results, refer to the Hormonal IUD Access Portal website at www.hormonaliud.org.
↵b X = data available.
↵c (x) = Some data collected but quantity/quality limited. Assessment of the current status of evidence based on review and assessment of existing data from each country and project.